Skip to main
STAA
STAA logo

STAAR Surgical (STAA) Stock Forecast & Price Target

STAAR Surgical (STAA) Analyst Ratings

Based on 13 analyst ratings
Buy
Strong Buy 54%
Buy 0%
Hold 38%
Sell 8%
Strong Sell 0%

Bulls say

Staar Surgical Co is projected to achieve normalized sales of $156 million in 2026, reflecting a year-over-year growth of 7% due to anticipated market growth and increasing market share in implantable Collamer lenses (ICLs). The company is strategically positioned for expansion with initiatives such as a faster domestic launch of its EVO product and enhanced international adoption, which are expected to drive long-term growth and margin improvement. Additionally, the leadership's focus on streamlining operations and reducing costs is expected to bolster revenue growth and enhance overall profitability.

Bears say

Staar Surgical Co. is facing significant headwinds due to elevated inventory levels with its new distributor in China, leading to a revenue recognition shortfall that adversely impacted 4Q24 results. The company’s bear case scenario suggests that revenue growth may remain flat or decline, exacerbated by potential risks from weak sales and market share losses to lower-cost alternatives. Additionally, broader macroeconomic challenges, coupled with pressures from rising patient out-of-pocket costs and geopolitical risks, further contribute to a negative outlook for Staar Surgical's stock.

STAAR Surgical (STAA) has been analyzed by 13 analysts, with a consensus rating of Buy. 54% of analysts recommend a Strong Buy, 0% recommend Buy, 38% suggest Holding, 8% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of STAAR Surgical and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About STAAR Surgical (STAA) Forecast

Analysts have given STAAR Surgical (STAA) a Buy based on their latest research and market trends.

According to 13 analysts, STAAR Surgical (STAA) has a Buy consensus rating as of Jun 21, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $53.23, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $53.23, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

STAAR Surgical (STAA)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.